“We can’t take the orphan drug revolution for granted.“ Biorasi’s Few & Far Between Podcast welcomes Jim Geraghty, author and biotech industry veteran, to discuss the necessity and viability of orphan and rare disease research - for both patients and VC investors alike.
"In research or in biotech, time is expensive. Time is the most expensive thing that you have." - Stephanie Wisner, Author, Co-Founder at Centivax...
How do mission, vision, and data analysis fit into today's biotech goals? Host Chris O'Brien welcomes Frank David, Founder and Managing Director of Pharmagellan...
The challenge? Decoding the human immune system. Get ready to meet the top challenger on today's episode of the Biorasi Few & Far Between...